Executive Summary

The inaugural edition of Section 16 Insider opens with a day dominated by insider dispositions. Eric Lefkofsky, CEO and Chairman of Tempus AI (TEM), sold $7.71 million worth of common stock across six separate transactions on March 25-26, representing the single largest insider disposal in today's filing batch. With TEM trading around $46, Lefkofsky's selling pace is notable — though not unusual for a founder-CEO with concentrated holdings.

On the buy side, activity was anemic. The only open-market purchase came from William Houlihan at Lument Finance Trust (LFT), a micro-cap mortgage REIT, where he acquired 15,000 shares at $1.29 for a total of just $19,350. The extreme asymmetry — $19K in buys vs. $12.6M in sells — gives us a buy/sell ratio of 0.002, far below the historical average of ~0.35. This suggests insiders are broadly in distribution mode heading into Q1 earnings season.

Today's top signals:

1. Lefkofsky/TEM — $7.7M CEO sale across six transactions. Is this 10b5-1 plan execution or discretionary selling before a catalyst?

2. Selick/PTGX — Director exercised options at $12.88 and immediately sold at $105 for $2.5M — a 715% gain between exercise and sale price

3. McMillon/WMT — Walmart director sold $2.4M in stock. Routine for a board member at a $600B+ company, but size warrants monitoring

4. Houlihan/LFT — The lone open-market buyer. At $1.29/share, this is a deep-value conviction bet on a beaten-down mortgage REIT

5. DUOL — CFO Gillian Munson received 133,753 RSU shares, the largest equity grant in today's filings

With Q1 earnings season approaching in April, the heavy selling bias may reflect insiders locking in gains ahead of blackout periods rather than signaling fundamental weakness. But the near-total absence of buying is a data point worth watching over the coming week.

Today In Numbers

The 0.002 buy/sell ratio is one of the lowest readings possible — only a single open-market buy against over $12 million in sells. While a single day's data is noisy (especially with weekend filing lag), this extreme skew historically correlates with market caution among corporate insiders.

High-Conviction Insider Buys

William Houlihan at Lument Finance Trust (LFT) — $19,350

Date: March 26, 2026

Transaction: 15,000 shares at $1.29 per share ($19,350 total)

Post-transaction holdings: 255,732 shares (~$330K at current price)

Insider profile: Non-officer, non-director position (no title listed). Already holds a significant position relative to the stock's micro-cap status

Company context: LFT is a mortgage REIT focused on floating-rate bridge loans to middle-market commercial real estate borrowers. Trading at $1.29, the stock is deeply depressed, suggesting severe market skepticism about the CRE lending book. SIC code 6159 (Federal and Federally-Sponsored Credit Agencies)

Why it matters: This is a pure conviction buy — no option exercise, no grant vesting, no tax-driven mechanical transaction. At $1.29/share, Houlihan is buying into extreme distress. The $19K size is modest in absolute terms but represents someone increasing their exposure to a stock that most institutional investors have abandoned

Historical signal: Open-market purchases in deeply distressed REITs (sub-$2 share price) have historically preceded either takeout offers, asset sales, or — in worst cases — further declines toward zero. The signal is binary: either Houlihan knows the book value is real, or this is the proverbial catching of a falling knife

The signal: A small but meaningful open-market buy in a distressed mortgage REIT — the kind of transaction that only happens when the insider sees value that the market has given up on.

This was the only open-market purchase in today's entire filing batch, making it a standout by default. The absence of any other buying activity across 25 filings amplifies its significance, even at a modest dollar amount.

Notable Insider Selling

1. Eric Lefkofsky, CEO & Chairman — Tempus AI (TEM): $7,711,150

Dates: March 25-26, 2026

Transactions: Six sales totaling 166,250 shares at prices ranging from $45.78 to $47.42

65,559 shares @ $45.78 = $3,001,291

59,657 shares @ $46.91 = $2,798,510

16,388 shares @ $45.78 = $750,243

14,915 shares @ $46.91 = $699,663

7,784 shares @ $47.42 = $369,117

1,947 shares @ $47.42 = $92,327

Classification: The multiple price points and varying lot sizes suggest discretionary selling, not a clean 10b5-1 plan execution (which typically shows uniform pricing). However, Lefkofsky is a founder with highly concentrated holdings, so some diversification selling is expected

Why it matters: Lefkofsky is a serial entrepreneur (Groupon co-founder) who took Tempus public. TEM is an AI-driven precision medicine company — a sector attracting premium valuations. A CEO selling $7.7M while the stock is around $46 could signal either routine liquidity needs or concerns about near-term catalysts

The bear case: At scale, even 166K shares is a modest percentage of a founder-CEO's total position. This may be systematic diversification rather than a signal about company fundamentals

2. Harold Selick, Director — Protagonist Therapeutics (PTGX): $2,520,000

Filing: Form 4, SEC EDGAR

Date: March 26, 2026

Transactions: Exercised options for 24,000 shares at $12.88 (cost: $309,120), then sold 24,000 shares at $105.00 ($2,520,000)

Profit on exercise: $2,210,880 (715% gain from exercise price to sale price)

Classification: Option exercise + immediate sell — typically tax-driven, as the insider needs cash to cover the tax liability on the exercise spread. Less informative than a pure discretionary sell

Context: PTGX at $105 represents a biotech that has performed well. The massive gap between exercise price ($12.88) and market ($105) suggests these are deep-in-the-money options from years ago, now being monetized

The signal: Likely tax optimization rather than a directional bet. The 715% spread makes this an almost mechanical exercise-and-sell

3. C. Douglas McMillon, Director — Walmart (WMT): $2,391,280

Filing: Form 4, SEC EDGAR

Date: March 26, 2026

Transaction: 19,416 shares at $123.16 ($2,391,280). Post-transaction holdings: 4,213,406 shares (~$519M)

Classification: McMillon holds over 4.2 million shares. The sale of 19K shares represents 0.46% of his total position

The signal: Noise, not signal. When a director/CEO with $519M in stock sells $2.4M, it's rounding error

4. Nathaniel Gandert, CTO — Getty Images (GETY): $16,652

Filing: Form 4, SEC EDGAR

Transaction: 21,349 shares at $0.78 = $16,652

Context: GETY trading at $0.78 — deeply distressed stock. A CTO selling at sub-$1 levels is mildly concerning

The signal: Small in dollar terms but potentially meaningful as a sentiment indicator at a struggling company

5. Michael Feld, EVP & Chief Revenue Officer — Becton Dickinson (BDX): $11,762

Filing: Form 4

Transaction: 75 shares at $156.83 ($11,762)

Classification: Trivially small for a C-suite executive at a $60B+ med-tech company. Likely tax-related or automatic plan execution

The signal: No informational content

Cluster Activity

Today's cluster activity is dominated by routine equity compensation events — spring RSU vesting cycles at Concentrix, Yum China, and ACCO Brands. These are mechanical, calendar-driven, and carry no directional signal.

The Village Super Market (VLGEA) cluster is the most interesting: both CEO John Sumas and insider Perry Blatt had large share dispositions via code F (tax withholding) on vested equity, with combined value over $1.1M.

No true cluster buying events detected today — zero companies had multiple insiders purchasing shares in the open market.

Sector Heat Map

The sector picture is uniformly bearish across the board, with zero open-market buying in any sector except distressed mortgage REITs.

Strategic Deep Dive

Eric Lefkofsky's $7.7M Tempus AI Exit: Founder Diversification or Pre-Catalyst Signal?

Eric Lefkofsky is no stranger to insider selling scrutiny. As co-founder and CEO of Groupon, his selling patterns were closely watched — and ultimately proved prescient as the stock declined 90%+ from its IPO highs. Now at the helm of Tempus AI (TEM), his $7.7 million in sales over two trading days demands the same forensic attention.

The facts: Lefkofsky sold 166,250 shares across six transactions on March 25-26, at prices between $45.78 and $47.42, for total proceeds of $7,711,150. The multiple price points and lot sizes suggest these were market orders executed in tranches, not the clean, predetermined executions typical of 10b5-1 plans.

Tempus AI context: TEM is a technology company applying AI to precision medicine — genomic sequencing, clinical data structuring, and clinical trial matching. The company has been a market darling in the AI healthcare space, benefiting from the broader AI investment boom. At ~$46/share, TEM has a market cap roughly in the $8-10B range.

The bull case for ignoring this sale: Lefkofsky is a founder-CEO with massively concentrated holdings in TEM. Selling $7.7M — while large in absolute terms — may represent only 1-3% of his total equity stake. Founders regularly diversify to fund lifestyle, charitable commitments, or other investments.

The bear case: Six separate sales over two days suggests urgency or a desire to move quickly before a potential catalyst. If Lefkofsky has visibility into Q1 results, pipeline developments, or regulatory decisions, the timing could be informative.

Historical parallel: When Lefkofsky sold Groupon shares aggressively in 2012-2013, the stock subsequently declined from $20+ to under $5 over the following 18 months.

Three scenarios:

Bull case (40%): Sales are routine diversification. TEM continues to execute on its AI precision medicine platform. Stock at $55-60 in 90 days.

Neutral case (35%): Sales have no directional significance. TEM trades sideways in the $42-50 range through Q1 earnings.

Bear case (25%): Lefkofsky is front-running negative news. Stock retraces to $35-38 on earnings disappointment.

The contrarian take: The market has largely become desensitized to Lefkofsky's selling because he has sold periodically since TEM's IPO. This desensitization could be the most dangerous aspect — if the market discounts the signal as "routine" when it's actually informative, the smart money will miss the exit. Watch for follow-up filings from other TEM insiders in the next 7-14 days.

Macro Context

Today's insider activity lands in a market environment where the S&P 500 has been navigating uncertainty around tariff policy, Federal Reserve rate trajectory, and Q1 earnings expectations. With the VIX recently showing elevated readings, one would normally expect opportunistic insider buying during periods of market fear — yet today's filings show the opposite.

The extreme sell bias (buy/sell ratio of 0.002 vs. historical ~0.35) is noteworthy in context. While a single day of filings — especially one affected by weekend submission lag — is insufficient to declare a trend, this data point adds to a pattern of insider caution heading into April. Corporate insiders tend to reduce buying activity 2-3 weeks before earnings blackout periods begin, and many companies enter blackout in early-to-mid April for Q1 reporting.

The Fed Funds rate and 10-Year minus 2-Year Treasury spread are key context variables for interpreting insider behavior in rate-sensitive sectors. The sole open-market buy today (Houlihan at LFT) was in a mortgage REIT — a sector that benefits from yield curve steepening and rate cuts. If this insider is making a macro bet on lower rates ahead, it could signal expectations about Fed policy that haven't been fully priced into the REIT sector.

Aggregate insider activity flows over the past week should be watched for confirmation. If the next 3-5 trading days continue to show sub-0.10 buy/sell ratios, it would represent one of the most bearish insider sentiment readings of 2026 — a signal that historically has preceded market corrections of 3-7% within 30-60 days.

What We'Re Watching Tomorrow

1. Tempus AI (TEM) follow-up filings: Will other TEM insiders follow Lefkofsky's selling? A cluster sell from the C-suite would significantly amplify today's bearish signal. Check EDGAR for Form 4 filings from TEM's CFO and COO.

2. Monday filing surge: Weekend Form 4 submissions typically process Monday morning. Expect 200+ filings as the backlog clears — this will give us a much cleaner picture of true insider sentiment.

3. Lument Finance Trust (LFT) — follow-through buying: Houlihan's $19K buy was the sole open-market purchase today. If additional LFT insiders file purchases early next week, it would signal genuine conviction in the distressed REIT.

4. Protagonist Therapeutics (PTGX) — post-exercise monitoring: After Selick's $2.5M exercise-and-sell at $105, watch for whether PTGX has any upcoming FDA catalysts or clinical readouts that could explain the timing.

5. Q1 Blackout Period Onset: Many large-cap companies enter trading blackout periods in early April. Expect insider buying to decline further next week as compliance departments restrict trading. Any purchases that DO occur during this window carry amplified signal value.

6. Duolingo (DUOL) — CFO equity grant: Gillian Munson received 133,753 RSU shares. Monitor for any subsequent sales — CFOs selling shortly after a major grant can indicate concerns about near-term financials.

7. Village Super Market (VLGEA) — Both CEO and another insider had large tax withholdings on vested equity. At $42.79 for a regional grocery chain, watch for any open-market purchases that would signal the CEO sees value.